These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9833164)

  • 1. Tolerability of a modern antihypertensive agent: candesartan cilexetil.
    Andersson OK
    Basic Res Cardiol; 1998; 93 Suppl 2():54-8. PubMed ID: 9833164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
    Andersson OK; Neldam S
    Blood Press; 1998 Jan; 7(1):53-9. PubMed ID: 9551878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
    Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S; Stirling AL
    Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P; Reismann J; Pohlmeyer H; Düsing R
    Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT; O'Kane KP; Jonker J; Roth J
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS
    J Hypertens Suppl; 1997 Dec; 15(6):S9-12. PubMed ID: 9493121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
    Kloner RA; Weinberger M; Pool JL; Chrysant SG; Prasad R; Harris SM; Zyczynski TM; Leidy NK; Michelson EL;
    Am J Cardiol; 2001 Mar; 87(6):727-31. PubMed ID: 11249891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS
    Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candesartan cilexetil. A review of its use in essential hypertension.
    McClellan KJ; Goa KL
    Drugs; 1998 Nov; 56(5):847-69. PubMed ID: 9829158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
    Ogihara T; Arakawa K
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.
    McInnes GT; O'Kane KP; Istad H; Keinänen-Kiukaanniemi S; Van Mierlo HF
    J Hum Hypertens; 2000 Apr; 14(4):263-9. PubMed ID: 10805052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candesartan cilexetil: an update of its use in essential hypertension.
    Easthope SE; Jarvis B
    Drugs; 2002; 62(8):1253-87. PubMed ID: 12010090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.
    Oparil S
    Am J Cardiol; 1999 Nov; 84(10A):35S-41S. PubMed ID: 10588093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators.
    Zuschke CA; Keys I; Munger MA; Carr AA; Marinides GN; Flanagan TL; Cushing DJ; Hayes JL; Michelson EL
    Clin Ther; 1999 Mar; 21(3):464-74. PubMed ID: 10321416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
    Lacourcière Y; Asmar R
    Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
    Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.